We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ISRG Trading 4% Below All-Time High: Should You Buy the Stock Now?
Read MoreHide Full Article
Key Takeaways
ISRG posted 20% worldwide procedure growth in Q3, led by da Vinci gains and rapid Ion expansion.
ISRG saw utilization rise as 240 da Vinci 5 systems were placed, lifting the global installed base.
ISRG generates 85% of revenues from recurring sales, driven by da Vinci 5 features and upgrades.
Intuitive Surgical (ISRG - Free Report) stock has delivered a strong recent run, rising 32.4% over the past three months and currently trading at $592.85, just 3.8% below its all-time high of $616 reached in February 2025. This rally reflects growing investor confidence in the company’s operating momentum, particularly following a robust third-quarter earnings performance.
With shares hovering near record levels, the key question for investors is whether Intuitive Surgical’s fundamentals, especially procedure growth and the early impact of da Vinci 5, support further upside or suggest a pause after the recent surge. ISRG has outperformed its peers — Medtronics (MDT - Free Report) and PROCEPT BioRobotics (PRCT - Free Report) — in the past three months. While MDT has gained 2.5%, PRCT declined 0.1%.
ISRG’s 3-Months Price Performance
Image Source: Zacks Investment Research
ISRG Rides on Procedure Growth and Rising Utilization
Procedure growth remains the backbone of Intuitive Surgical’s long-term value creation, and third-quarter results reinforced its strength. Total worldwide procedures grew 20% year over year, driven by 19% growth in da Vinci procedures and a 52% increase in Ion procedures.
Importantly, this growth was not isolated to a single geography or specialty. Management cited strength in U.S. benign general surgery, such as cholecystectomy, appendectomy, and hernia repair, alongside broad-based international growth across general surgery, gynecology, colorectal and thoracic procedures.
Utilization trends further strengthened the investment case. Average system utilization increased 4% for da Vinci multiport, 35% for SP, and 14% for Ion, reflecting rising throughput within the installed base. Management emphasized that da Vinci 5 utilization is already outpacing the earlier Xi platform at a comparable stage, validating the system’s design intent to support higher efficiency. This combination of procedural expansion and utilization leverage supports recurring revenue growth and reduces dependence on pure system placements for top-line acceleration.
Potential for Accelerated Revenue Growth With da Vinci 5 Adoption
The broad launch of da Vinci 5 is emerging as a key catalyst for incremental revenue growth. During the third quarter, Intuitive Surgical placed 240 da Vinci 5 systems, bringing the installed base to 929 systems globally. Upgrade-driven demand was particularly strong in the United States, with 141 trade-in transactions, as hospitals sought to expand throughput and modernize fleets rather than add incremental capacity.
Crucially, da Vinci 5 is not merely replacing older systems — it is driving higher engagement. Management highlighted that nearly 90% of da Vinci 5 procedures utilized integrated insufflation technology, underscoring rapid adoption of platform-specific features.
Higher utilization, combined with a greater mix of da Vinci 5-specific instruments and accessories, supports recurring revenue growth, which already accounts for 85% of total revenues. As da Vinci 5 penetration increases across large health systems and international markets, Intuitive Surgical is positioned to compound revenue growth through both volume and mix.
Revenue & EPS Estimates
Image Source: Zacks Investment Research
Follow-on Feature Releases for da Vinci 5
Beyond initial adoption, Intuitive Surgical’s strategy for da Vinci 5 centers on continuous enhancement through software and hardware updates. In third-quarter, the company received FDA 510(k) clearance for the first in a series of software releases, enabling remote deployment via Network Central Configuration Management. This capability reduces operational friction for hospitals and strengthens the long-term value of the installed base.
Additional features introduced include Force Gauge and Focus Mode, which provide visual force representation, in-console video replay and 3D model manipulation. Early clinical data discussed on the call showed reductions in applied surgical force when force feedback is used, supporting the potential for gentler surgery and improved learning curves.
Management framed these releases as foundational, with future updates expected to further integrate digital tools, AI-driven insights and intraoperative guidance, deepening differentiation and reinforcing switching costs over time.
Competition Update
Rising competition in surgical robotics extends beyond Medtronic’s Hugo platform to other emerging U.S.-listed rivals, such as Procept BioRobotics, which recently received FDA clearance for its AI-powered HYDROS robotic system for urology and benign prostatic hyperplasia. Both Medtronic’s Hugo and Procept BioRobotics’ HYDROS target procedure growth and utilization gains that could erode parts of Intuitive Surgical’s dominance in specific indications.
Medtronic’s Hugo offers a modular, multi-specialty approach, while Procept BioRobotics focuses on autonomous tissue removal in urology; together, they signal intensifying competitive pressure within the robotic surgery market.
Estimate Revision Trend for ISRG
Estimates for Intuitive Surgical’s 2025 earnings have moved up 8.5% to $8.65 per share over the past year, while the same for 2026 earnings has improved 2.6% to $9.61. The positive estimate revision depicts bullish sentiments for the stock.
Image Source: Zacks Investment Research
Conclusion
Although ISRG shares are trading just below all-time highs, the valuation remains well below the five-year peak reached in February last year. Moreover, third-quarter results suggest that Intuitive Surgical’s recent stock rally is grounded in tangible operational momentum.
Sustained procedure growth, rising utilization, accelerating da Vinci 5 adoption, and a robust pipeline of follow-on feature releases position the company for durable growth into 2026. For investors with a long-term horizon, the current pullback from peak levels may represent an opportunity to gain exposure to a structurally strengthening robotics platform rather than a signal to step aside.
Image: Shutterstock
ISRG Trading 4% Below All-Time High: Should You Buy the Stock Now?
Key Takeaways
Intuitive Surgical (ISRG - Free Report) stock has delivered a strong recent run, rising 32.4% over the past three months and currently trading at $592.85, just 3.8% below its all-time high of $616 reached in February 2025. This rally reflects growing investor confidence in the company’s operating momentum, particularly following a robust third-quarter earnings performance.
With shares hovering near record levels, the key question for investors is whether Intuitive Surgical’s fundamentals, especially procedure growth and the early impact of da Vinci 5, support further upside or suggest a pause after the recent surge. ISRG has outperformed its peers — Medtronics (MDT - Free Report) and PROCEPT BioRobotics (PRCT - Free Report) — in the past three months. While MDT has gained 2.5%, PRCT declined 0.1%.
ISRG’s 3-Months Price Performance
Image Source: Zacks Investment Research
ISRG Rides on Procedure Growth and Rising Utilization
Procedure growth remains the backbone of Intuitive Surgical’s long-term value creation, and third-quarter results reinforced its strength. Total worldwide procedures grew 20% year over year, driven by 19% growth in da Vinci procedures and a 52% increase in Ion procedures.
Importantly, this growth was not isolated to a single geography or specialty. Management cited strength in U.S. benign general surgery, such as cholecystectomy, appendectomy, and hernia repair, alongside broad-based international growth across general surgery, gynecology, colorectal and thoracic procedures.
Utilization trends further strengthened the investment case. Average system utilization increased 4% for da Vinci multiport, 35% for SP, and 14% for Ion, reflecting rising throughput within the installed base. Management emphasized that da Vinci 5 utilization is already outpacing the earlier Xi platform at a comparable stage, validating the system’s design intent to support higher efficiency. This combination of procedural expansion and utilization leverage supports recurring revenue growth and reduces dependence on pure system placements for top-line acceleration.
Potential for Accelerated Revenue Growth With da Vinci 5 Adoption
The broad launch of da Vinci 5 is emerging as a key catalyst for incremental revenue growth. During the third quarter, Intuitive Surgical placed 240 da Vinci 5 systems, bringing the installed base to 929 systems globally. Upgrade-driven demand was particularly strong in the United States, with 141 trade-in transactions, as hospitals sought to expand throughput and modernize fleets rather than add incremental capacity.
Crucially, da Vinci 5 is not merely replacing older systems — it is driving higher engagement. Management highlighted that nearly 90% of da Vinci 5 procedures utilized integrated insufflation technology, underscoring rapid adoption of platform-specific features.
Higher utilization, combined with a greater mix of da Vinci 5-specific instruments and accessories, supports recurring revenue growth, which already accounts for 85% of total revenues. As da Vinci 5 penetration increases across large health systems and international markets, Intuitive Surgical is positioned to compound revenue growth through both volume and mix.
Revenue & EPS Estimates
Image Source: Zacks Investment Research
Follow-on Feature Releases for da Vinci 5
Beyond initial adoption, Intuitive Surgical’s strategy for da Vinci 5 centers on continuous enhancement through software and hardware updates. In third-quarter, the company received FDA 510(k) clearance for the first in a series of software releases, enabling remote deployment via Network Central Configuration Management. This capability reduces operational friction for hospitals and strengthens the long-term value of the installed base.
Additional features introduced include Force Gauge and Focus Mode, which provide visual force representation, in-console video replay and 3D model manipulation. Early clinical data discussed on the call showed reductions in applied surgical force when force feedback is used, supporting the potential for gentler surgery and improved learning curves.
Management framed these releases as foundational, with future updates expected to further integrate digital tools, AI-driven insights and intraoperative guidance, deepening differentiation and reinforcing switching costs over time.
Competition Update
Rising competition in surgical robotics extends beyond Medtronic’s Hugo platform to other emerging U.S.-listed rivals, such as Procept BioRobotics, which recently received FDA clearance for its AI-powered HYDROS robotic system for urology and benign prostatic hyperplasia. Both Medtronic’s Hugo and Procept BioRobotics’ HYDROS target procedure growth and utilization gains that could erode parts of Intuitive Surgical’s dominance in specific indications.
Medtronic’s Hugo offers a modular, multi-specialty approach, while Procept BioRobotics focuses on autonomous tissue removal in urology; together, they signal intensifying competitive pressure within the robotic surgery market.
Estimate Revision Trend for ISRG
Estimates for Intuitive Surgical’s 2025 earnings have moved up 8.5% to $8.65 per share over the past year, while the same for 2026 earnings has improved 2.6% to $9.61. The positive estimate revision depicts bullish sentiments for the stock.
Image Source: Zacks Investment Research
Conclusion
Although ISRG shares are trading just below all-time highs, the valuation remains well below the five-year peak reached in February last year. Moreover, third-quarter results suggest that Intuitive Surgical’s recent stock rally is grounded in tangible operational momentum.
Sustained procedure growth, rising utilization, accelerating da Vinci 5 adoption, and a robust pipeline of follow-on feature releases position the company for durable growth into 2026. For investors with a long-term horizon, the current pullback from peak levels may represent an opportunity to gain exposure to a structurally strengthening robotics platform rather than a signal to step aside.
With a Zacks Rank #2 (Buy), Intuitive Surgical appears to be a potential addition to one’s portfolio. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.